Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Despite a significant increase in women with unilateral breast cancer who received a bilateral mastectomy, this study found no survival benefit compared with other treatment options. Although removing the unaffected breast reduces the risk of developing cancer in the other breast, results did not show decreased risk of death from breast cancer.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

A remote monitoring app with alerts for doctors did not improve medication adherence in patients with breast cancer, but those receiving tailored text messages on top of monitoring saw reduced high-cost health care use.

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

Early data suggest that BLU-222 combined with ribociclib and fulvestrant is safe and tolerable for patients with HR-positive and HER2-negative breast cancer, potentially overcoming resistance to CDK4/6 inhibitors.

The FDA approved SH-105 (Tepylute) prediluted injectable treatment for breast and ovarian cancers. This innovative formulation eliminates the need for complex powder reconstitution, improving safety and patient care.